386 related articles for article (PubMed ID: 17085455)
1. Effect of education on overall and cause-specific mortality in injecting drug users, according to HIV and introduction of HAART.
Jarrin I; Lumbreras B; Ferreros I; Pérez-Hoyos S; Hurtado I; Hernández-Aguado I
Int J Epidemiol; 2007 Feb; 36(1):187-94. PubMed ID: 17085455
[TBL] [Abstract][Full Text] [Related]
2. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users.
Ferreros I; Lumbreras B; Hurtado I; Pérez-Hoyos S; Hernández-Aguado I
Addiction; 2008 Apr; 103(4):651-9. PubMed ID: 18339110
[TBL] [Abstract][Full Text] [Related]
3. [Mortality in a cohort of intravenous drug users before the introduction of potent HIV therapy].
Muga R; Egea JM; Navío M; Sirera G; Vall M; Tor J
Med Clin (Barc); 1999 May; 112(19):721-5. PubMed ID: 10394568
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
[TBL] [Abstract][Full Text] [Related]
5. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System?
Borrell C; Rodríguez-Sanz M; Pasarín MI; Brugal MT; García-de-Olalla P; Marí-Dell'Olmo M; Caylà J
Eur J Public Health; 2006 Dec; 16(6):601-8. PubMed ID: 16698886
[TBL] [Abstract][Full Text] [Related]
6. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
7. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Larsen CS; Jensen J; Obel N; Kronborg G
Addiction; 2010 Mar; 105(3):529-35. PubMed ID: 20402997
[TBL] [Abstract][Full Text] [Related]
8. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
9. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
[TBL] [Abstract][Full Text] [Related]
10. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
11. HIV related and non-HIV related mortality before and after the introduction of highly active antiretroviral therapy (HAART) in Norway compared to the general population.
Ormaasen V; Sandvik L; Dudman SG; Bruun JN
Scand J Infect Dis; 2007; 39(1):51-7. PubMed ID: 17366013
[TBL] [Abstract][Full Text] [Related]
12. Mortality is influenced by locality in a major HIV/AIDS epidemic.
Druyts EF; Rachlis BS; Lima VD; Harvard SS; Zhang W; Brandson EK; Strathdee SA; Montaner JS; Hogg RS
HIV Med; 2009 May; 10(5):274-81. PubMed ID: 19210694
[TBL] [Abstract][Full Text] [Related]
13. Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART.
Muga R; Ferreros I; Langohr K; de Olalla PG; Del Romero J; Quintana M; Alastrue I; Belda J; Tor J; Pérez-Hoyos S; Del Amo J;
AIDS; 2007 Nov; 21(18):2521-7. PubMed ID: 18025889
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.
Spittal PM; Craib KJ; Wood E; Laliberté N; Li K; Tyndall MW; O'Shaughnessy MV; Schechter MT
CMAJ; 2002 Apr; 166(7):894-9. PubMed ID: 11949985
[TBL] [Abstract][Full Text] [Related]
15. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART.
Lumbreras B; Jarrín I; del Amo J; Pérez-Hoyos S; Muga R; García-de la Hera M; Ferreros I; Sanvisens A; Hurtado I; Hernández-Aguado I
AIDS; 2006 Jan; 20(1):111-6. PubMed ID: 16327326
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status.
Moreno S; Jarrin I; Iribarren JA; Perez-Elías MJ; Viciana P; Parra-Ruiz J; Gomez-Sirvent JL; Lopez-Aldeguer J; Gutierrez F; Blanco JR; Vidal F; Leal M; Rodríguez Arenas MA; Del Amo J;
Int J Tuberc Lung Dis; 2008 Dec; 12(12):1393-400. PubMed ID: 19017448
[TBL] [Abstract][Full Text] [Related]
17. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
18. [Mortality and causes of death among intravenous drug addicts in Oslo].
Eskild A; Magnus P; Samuelsen SO; Sohlberg C; Kittelsen P
Tidsskr Nor Laegeforen; 1993 Apr; 113(11):1331-3. PubMed ID: 8337619
[TBL] [Abstract][Full Text] [Related]
19. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004.
Donoghoe MC; Bollerup AR; Lazarus JV; Nielsen S; Matic S
Int J Drug Policy; 2007 Aug; 18(4):271-80. PubMed ID: 17689375
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
